Revadix
Toulouse, FR · 1 known investors
Revadix develops first-in-class small molecule therapies targeting the EPAC1 signalling pathway to treat atrial fibrillation, addressing the underlying disease mechanism rather than symptoms. Its lead asset AM-001 is entering IND-enabling studies while a second EPAC1-targeting program is in lead optimization, aimed at cardiac arrhythmia patients.
Founders & leadership
FL
Frank Lezoualc'hScientific Founder / Research Director at Inserm
Investors · 1
Frequently asked questions
- What does Revadix do?
- Revadix develops first-in-class small molecule therapies targeting the EPAC1 signalling pathway to treat atrial fibrillation, addressing the underlying disease mechanism rather than symptoms. Its lead asset AM-001 is entering IND-enabling studies while a second EPAC1-targeting program is in lead optimization, aimed at cardiac arrhythmia patients.
- Who founded Revadix?
- Revadix was founded by Frank Lezoualc'h.
- Who are Revadix's investors?
- Revadix's investors include NLC.
- Where is Revadix headquartered?
- Revadix is headquartered in Toulouse, FR.